Lonza Agrees to Buy Five US CDMO Sites From Merck

• Lonza agreed to acquire five US contract development and manufacturing sites from Merck, expanding its US network from four to nine sites.
• The cash transaction carries an enterprise valuation in the low- to mid-triple-digit millions of Swiss francs.
• Closing is expected in mid-2027, subject to customary conditions, with funding from cash on hand and existing credit facilities.
• About 1,100 employees will transfer, taking the US workforce above 6,000 while expanding bioconjugate and viral vector capabilities.
• The acquired sites are expected to generate around CHF 250 million in 2028 sales, with a CORE EBITDA margin below the group's.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lonza Group Ltd. published the original content used to generate this news brief via EQS News (Ref. ID: adhoc_2427052_en) on November 03, 2026, and is solely responsible for the information contained therein.